Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 2/11/2026

Guideline Recommendations for Lyme Disease Treatment

First‑Line Oral Therapy for Early Lyme Disease

  • Adults and children ≥ 8 years with erythema migrans (early localized or early disseminated) should receive one of the following oral regimens: doxycycline 100 mg twice daily for 10–14 days, amoxicillin 500 mg three times daily for 14 days, or cefuroxime axetil 500 mg twice daily for 14 days. (IDSA/AAN/ACR) 1

  • Preferred adult regimen: doxycycline 100 mg twice daily for 10–14 days, because it also covers possible concurrent human granulocytic anaplasmosis (HGA). (IDSA/AAN/ACR) 1

  • Alternative adult agents (when doxycycline is contraindicated): amoxicillin 500 mg three times daily for 14 days or cefuroxime axetil 500 mg twice daily for 14 days. (IDSA/AAN/ACR) 2

  • Children ≥ 8 years: doxycycline 4 mg/kg/day divided twice daily (maximum 100 mg per dose) for 10–14 days; alternatives are amoxicillin 50 mg/kg/day divided three times daily (max 500 mg per dose) or cefuroxime axetil 30 mg/kg/day divided twice daily (max 500 mg per dose) for 14 days. (IDSA/AAN/ACR) 1

  • Children < 8 years: amoxicillin 50 mg/kg/day divided three times daily (max 500 mg per dose) for 14 days is preferred; cefuroxime axetil 30 mg/kg/day divided twice daily (max 500 mg per dose) is an acceptable alternative. (IDSA/AAN/ACR) 1

  • Doxycycline: 10 days; amoxicillin or cefuroxime axetil: 14 days for erythema migrans, reflecting the 2020 IDSA/AAN/ACR guideline update. (IDSA/AAN/ACR) 3
  • Evidence strength: high‑quality studies demonstrate that a 10‑day doxycycline course is equivalent in efficacy to longer regimens. (IDSA/AAN/ACR) [4][5]

Second‑Line Oral Options (Macrolides)

  • Macrolides are markedly less effective than first‑line agents and should be reserved for patients who cannot tolerate doxycycline, amoxicillin, and cefuroxime axetil. (IDSA/AAN/ACR) 6

  • Adult dosing: azithromycin 500 mg daily for 7–10 days (7 days preferred in the United States); clarithromycin 500 mg twice daily for 14–21 days (avoid in pregnancy); erythromycin 500 mg four times daily for 14–21 days. (IDSA/AAN/ACR) 6

  • Pediatric dosing: azithromycin 10 mg/kg/day (max 500 mg/day); clarithromycin 7.5 mg/kg twice daily (max 500 mg per dose); erythromycin 12.5 mg/kg four times daily (max 500 mg per dose). (IDSA/AAN/ACR) 6

  • Monitoring requirement: patients receiving macrolides need close clinical follow‑up because treatment failures are more common. (IDSA/AAN/ACR) 6

Parenteral Therapy for Severe or Late Manifestations

Early Neurologic Disease (Meningitis, Radiculopathy)

  • Ceftriaxone 2 g IV once daily for 14 days (range 10–28 days) is the standard regimen. (IDSA/AAN/ACR) 1

  • Pediatric dosing: 50–75 mg/kg IV once daily (max 2 g) for 14 days; alternatives include cefotaxime 150–200 mg/kg/day IV divided 3–4 times (max 6 g/day) or penicillin G 200,000–400,000 units/kg/day IV every 4 hours (max 18–24 million units/day). (IDSA/AAN/ACR) 7

  • Isolated cranial nerve palsy without meningeal signs may be managed with the same oral regimens used for erythema migrans for 14–21 days; lumbar puncture is optional, and parenteral therapy is indicated if CSF pleocytosis is present. (IDSA/AAN/ACR) 7

Late Neurologic Disease (≥ 6 months)

  • Ceftriaxone 2 g IV daily for 21 days (3 weeks). (IDSA/AAN/ACR) 7

Lyme Carditis

  • Oral or IV therapy for 14–21 days; hospitalization with continuous cardiac monitoring is advised for symptomatic patients, second‑ or third‑degree AV block, or first‑degree block with PR ≥ 300 ms. (IDSA/AAN/ACR) 7

  • Oral regimens: same as for erythema migrans. (IDSA/AAN/ACR) 7

  • IV regimen: ceftriaxone 2 g once daily. (IDSA/AAN/ACR) 7

Lyme Arthritis (Severe or Oral‑Failure)

  • Parenteral ceftriaxone 2 g IV daily for 14–28 days when oral therapy fails or arthritis is severe. (IDSA/AAN/ACR) 1

Special Populations

  • Pregnancy & lactation: treat identically to non‑pregnant patients except doxycycline must be avoided. Use amoxicillin or cefuroxime axetil for early disease and ceftriaxone for neurologic or severe disease. (IDSA/AAN/ACR) [1][8]

  • Renal impairment: dosage adjustments are required for parenteral agents (e.g., ceftriaxone, cefotaxime, penicillin G). (IDSA/AAN/ACR) 1

  • First‑generation cephalosporins (e.g., cephalexin), fluoroquinolones, long‑term (> 28 days) antibiotic courses, combination antimicrobial regimens, and pulsed‑dosing schedules are explicitly discouraged for any Lyme disease manifestation. (IDSA/AAN/ACR) [9][2]8

Coinfection Considerations

  • Assess for Babesia microti or Anaplasma phagocytophilum when: fever persists > 48 h despite appropriate Lyme therapy, unexplained leukopenia/thrombocytopenia/anemia, or unusually severe initial symptoms. (IDSA/AAN/ACR) 2

  • Doxycycline covers Lyme disease and HGA but does not treat babesiosis. (IDSA/AAN/ACR) 7

Ceftriaxone Use Guidance

  • Ceftriaxone is not superior to oral agents for early Lyme disease without neurologic involvement or advanced heart block and carries a higher risk of serious adverse effects. (IDSA/AAN/ACR) [1][8]

  • Reserve parenteral therapy for true indications: CNS involvement, advanced AV block, or documented treatment failure. (IDSA/AAN/ACR) 1

Doxycycline Administration Tips

  • Take with at least 8 oz (≈ 240 mL) of fluid to reduce esophageal irritation; it may be taken with food to lessen gastrointestinal upset. (IDSA/AAN/ACR) 9

  • Food or milk does not significantly affect doxycycline absorption. (IDSA/AAN/ACR) 9

  • Patients should be warned about photosensitivity and advised to avoid excessive sun exposure, especially during summer months. (IDSA/AAN/ACR) 4

Antibiotic Treatment Recommendations for Early Lyme Disease

First‑Line Oral Therapy

  • Doxycycline 100 mg orally twice daily for 10 days is as effective as amoxicillin 500 mg three times daily for 14 days in patients with early localized or early disseminated erythema migrans, providing comparable cure rates while improving treatment adherence【10】.
  • Doxycycline simultaneously treats Borrelia burgdorferi infection and human granulocytic anaplasmosis (AGH), a common tick‑borne co‑infection, offering dual antimicrobial coverage【10】.

Contra‑indications and Special Populations

  • In pregnancy and lactation, doxycycline is contraindicated; amoxicillin 500 mg three times daily for 14 days is the recommended oral regimen【10】.
  • For children younger than 8 years, doxycycline is avoided; amoxicillin 50 mg/kg/day divided into three doses (maximum 500 mg per dose) for 14 days is recommended【10】.
  • Doxycycline may cause photosensitivity; amoxicillin does not, making the latter preferable during summer months or for patients with high sun exposure【10】.
  • Amoxicillin is generally better tolerated gastrointestinally when taken with food, reducing esophageal irritation compared with doxycycline【10】.

Alternative Agents and Agents to Avoid

  • First‑generation cephalosporins (e.g., cefalexin) lack in‑vitro activity against B. burgdorferi and are clinically ineffective for Lyme disease【10】.
  • Macrolides (azithromycin, clarithromycin, erythromycin) are markedly less effective than doxycycline or amoxicillin and should be reserved only for patients intolerant to both doxycycline, amoxicillin, and cefuroxime axetil【10】.
  • When erythema migrans cannot be reliably distinguished from bacterial cellulitis, treatment with cefuroxime axetil or amoxicillin‑clavulanate (which cover both conditions) is advised rather than cefalexin【10】.

Parenteral Therapy Indications

  • Intravenous ceftriaxone is not superior to oral agents for uncomplicated early Lyme disease and carries a higher risk of serious adverse events. It is reserved for:
    • Early neuro‑Lyme with meningitis or radiculopathy (14 days)
    • Advanced atrioventricular block (14–21 days)【11】
    • Documented failure of oral therapy (14–28 days)

Comparative Efficacy

  • Multiple randomized controlled trials demonstrate that doxycycline, amoxicillin, and cefuroxime axetil are equally effective for early Lyme disease, achieving comparable cure rates; less than 10 % of patients fail to respond to initial oral therapy【10】.
  • The evidence supporting equal efficacy is Level A (multiple RCTs)【10】.

Co‑infection Considerations

  • Doxycycline provides coverage for Lyme disease and AGH but does not treat babesiosis; clinicians should evaluate for Babesia microti or Anaplasma phagocytophilum when fever persists >48 h despite appropriate therapy, unexplained cytopenias develop, or the initial presentation is unusually severe【10】.

REFERENCES

← Return to Home